% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bunse:136849,
author = {L. Bunse$^*$ and S. Pusch$^*$ and T. Bunse$^*$ and F.
Sahm$^*$ and K. Sanghvi$^*$ and M. Friedrich$^*$ and D.
Alansary and J. Sonner$^*$ and E. Green$^*$ and K.
Deumelandt$^*$ and M. Kilian$^*$ and C. Neftel and S. Uhlig
and T. Kessler$^*$ and A. von Landenberg$^*$ and A. S.
Berghoff$^*$ and K. Marsh and M. Steadman and D. Zhu and B.
Nicolay and B. Wiestler and M. Breckwoldt$^*$ and R. Al-Ali
and S. Karcher-Bausch$^*$ and M. Bozza$^*$ and I. Oezen$^*$
and M. Kramer$^*$ and J. Meyer$^*$ and A. Habel$^*$ and J.
Eisel$^*$ and G. Poschet and M. Weller and M. Preusser and
M. Nadji-Ohl and N. Thon and M. C. Burger$^*$ and P.
Harter$^*$ and M. Ratliff$^*$ and R. Harbottle$^*$ and A.
Benner$^*$ and D. Schrimpf$^*$ and J. Okun and C.
Herold-Mende and S. Turcan and S. Kaulfuss and H.
Hess-Stumpp and K. Bieback and D. P. Cahill and K. H.
Plate$^*$ and D. Hänggi and M. Dorsch and M. L. Suvà and
B. A. Niemeyer and A. von Deimling$^*$ and W. Wick$^*$ and
M. Platten$^*$},
title = {{S}uppression of antitumor {T} cell immunity by the
oncometabolite ({R})-2-hydroxyglutarate.},
journal = {Nature medicine},
volume = {24},
number = {8},
issn = {1546-170X},
address = {New York, NY},
publisher = {Nature America Inc.},
reportid = {DKFZ-2018-01287},
pages = {1192 - 1203},
year = {2018},
abstract = {The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced
by isocitrate dehydrogenase (IDH) mutations promotes
gliomagenesis via DNA and histone methylation. Here, we
identify an additional activity of R-2-HG: tumor
cell-derived R-2-HG is taken up by T cells where it induces
a perturbation of nuclear factor of activated T cells
transcriptional activity and polyamine biosynthesis,
resulting in suppression of T cell activity. IDH1-mutant
gliomas display reduced T cell abundance and altered calcium
signaling. Antitumor immunity to experimental syngeneic
IDH1-mutant tumors induced by IDH1-specific vaccine or
checkpoint inhibition is improved by inhibition of the
neomorphic enzymatic function of mutant IDH1. These data
attribute a novel, non-tumor cell-autonomous role to an
oncometabolite in shaping the tumor immune
microenvironment.},
cin = {G160 / L101 / G380 / F160 / L501 / C060},
ddc = {610},
cid = {I:(DE-He78)G160-20160331 / I:(DE-He78)L101-20160331 /
I:(DE-He78)G380-20160331 / I:(DE-He78)F160-20160331 /
I:(DE-He78)L501-20160331 / I:(DE-He78)C060-20160331},
pnm = {317 - Translational cancer research (POF3-317)},
pid = {G:(DE-HGF)POF3-317},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29988124},
doi = {10.1038/s41591-018-0095-6},
url = {https://inrepo02.dkfz.de/record/136849},
}